Amgen Inc - Ebitda

Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Ebitda" stands at 16.54 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Amgen Inc's third quarter result of 5.91 Billion USD for the item "Ebitda" represents an increase of 63.48 percent compared to it's second quarter result.

Also, Amgen Inc's third quarter result of 5.91 Billion USD for the item "Ebitda" represents an increase of 12.14 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 16.54 Billion USD for the item "Ebitda" represents an increase of 4.03 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 22.67 percent compared to the value the year prior.
The 1 year change in percent is 22.67.
The 3 year change in percent is 33.24.
The 5 year change in percent is 28.07.
The 10 year change in percent is 57.30.

The Serie's long term average value is 11.43 Billion United States Dollars. It's latest available value, on 09/30/2025, is 44.74 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2011, to it's latest available value, on 09/30/2025, is +184.18%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.